Technical Analysis for KALA - Kala Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| 20 DMA Support | Bullish | -2.67% | |
| Doji - Bullish? | Reversal | -2.67% | |
| Outside Day | Range Expansion | -2.67% | |
| 20 DMA Support | Bullish | -3.05% | |
| NR7 | Range Contraction | -3.05% | |
| Narrow Range Bar | Range Contraction | -3.05% | |
| Gapped Down | Weakness | -3.05% | |
| 20 DMA Support | Bullish | -4.59% |
| Alert | Time |
|---|---|
| Down 3% | 1 day ago |
| Down 2 % | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 1% | 1 day ago |
| Fell Below 20 DMA | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/11/2024
Kala Pharmaceuticals Inc. is a United States-based company that is developing ophthalmic treatments based on the Company’s Mucosal Penetrating Product (MPP) platform. The Company’s topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Its product development pipeline includes a 1% formulation of loteprednol etabonate to treat post-surgical ocular inflammation and pain; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, and a topically applied receptor tyrosine kinase inhibitir (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD).
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Pain Eye Inflammation Ophthalmic Macular Degeneration Tyrosine Kinase Retina Wet Age Related Macular Degeneration Glucocorticoids Receptor Tyrosine Kinase Retinal Disease Blepharitis Post Surgical Ocular Inflammation
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Pain Eye Inflammation Ophthalmic Macular Degeneration Tyrosine Kinase Retina Wet Age Related Macular Degeneration Glucocorticoids Receptor Tyrosine Kinase Retinal Disease Blepharitis Post Surgical Ocular Inflammation
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.2 |
| 52 Week Low | 5.1 |
| Average Volume | 11,533 |
| 200-Day Moving Average | 8.22 |
| 50-Day Moving Average | 7.22 |
| 20-Day Moving Average | 6.71 |
| 10-Day Moving Average | 6.83 |
| Average True Range | 0.36 |
| RSI (14) | 40.48 |
| ADX | 22.64 |
| +DI | 17.74 |
| -DI | 14.72 |
| Chandelier Exit (Long, 3 ATRs) | 6.23 |
| Chandelier Exit (Short, 3 ATRs) | 7.22 |
| Upper Bollinger Bands | 7.20 |
| Lower Bollinger Band | 6.23 |
| Percent B (%b) | 0.33 |
| BandWidth | 14.44 |
| MACD Line | -0.10 |
| MACD Signal Line | -0.11 |
| MACD Histogram | 0.011 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.84 | ||||
| Resistance 3 (R3) | 6.85 | 6.77 | 6.79 | ||
| Resistance 2 (R2) | 6.77 | 6.70 | 6.76 | 6.77 | |
| Resistance 1 (R1) | 6.66 | 6.65 | 6.62 | 6.65 | 6.76 |
| Pivot Point | 6.58 | 6.58 | 6.56 | 6.57 | 6.58 |
| Support 1 (S1) | 6.47 | 6.51 | 6.43 | 6.46 | 6.34 |
| Support 2 (S2) | 6.39 | 6.46 | 6.38 | 6.33 | |
| Support 3 (S3) | 6.28 | 6.39 | 6.31 | ||
| Support 4 (S4) | 6.27 |
